Downregulation of long noncoding RNA PVT1 attenuates paclitaxel resistance in glioma cells
Tiejun Song1,1, Lei Yan2,1, Kerui Cai2
1Department of Clinical Laboratory, The Second Affiliated Hospital of Mudanjiang Medical University, Mudanjiang 157011, Heilongjiang, China.
Background:
Drug resistance in clinical cancer treatment has become an issue.
Objective:
We focus on abnormally expressed lncRNAs in glioma and investigating the function of PVT1.
Methods:
The paclitaxel-resistant glioma cells SHG-44 RE was obtained through screening the SHG 44 cells that were cultured in medium containing a certain concentration of paclitaxel. Cell survival of SHG 44 RE and SHG 44 cells under the treatment of paclitaxel was detected by MTT assay. The aberrant expressed lncRNAs were screened out with microarray analysis. Further qRT-PCR was utilized to validate the expression of lncRNA PVT1 in the two cells. After manipulating the expression of PVT1, cell viability and apoptosis were measured by MTT and flow cytometry respectively.
Results:
LncRNA PVT1 was overexpressed in glioma cells SHG-44 RE compared with parent SHG-44 cells. Down-regulation of lncRNA PVT1 inhibited the SHG-44 RE cell viability and increased glioma SHG-44 RE cells apoptosis after paclitaxel treatment, suggesting that inhibition of lncRNA PVT1 improved paclitaxel sensibility in human glioma cells.
Conclusion:
Down-regulation of PVT1 could enhance chemosensitivity of paclitaxel, induce apoptosis of glioma cells and noteworthy inhibit glioma cells proliferation. Our findings of PVT1 could contribute to attenuate paclitaxel resistance in clinical medicine.
Insights
Drug resistance is a problem in cancer treatment. Inhibiting long non-coding RNA PVT1 (lncRNA PVT1) in glioma cells can overcome paclitaxel resistance, increasing cell death and reducing proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Drug resistance is a significant challenge in clinical cancer therapy.
- Aberrant expression of long non-coding RNAs (lncRNAs) is implicated in various cancers, including glioma.
- The role of specific lncRNAs, such as PVT1, in mediating drug resistance in glioma requires further investigation.
Purpose of the Study:
- To investigate the function of the long non-coding RNA PVT1 (lncRNA PVT1) in paclitaxel-resistant human glioma cells.
- To determine if targeting lncRNA PVT1 can overcome drug resistance in glioma treatment.
Main Methods:
- Paclitaxel-resistant glioma cells (SHG-44 RE) were established and compared to parent cells (SHG-44).
- Microarray analysis identified aberrantly expressed lncRNAs, with qRT-PCR validating lncRNA PVT1 overexpression in resistant cells.
- Cell viability and apoptosis were assessed using MTT assays and flow cytometry after manipulating lncRNA PVT1 expression.
Main Results:
- Long non-coding RNA PVT1 (lncRNA PVT1) was found to be significantly overexpressed in paclitaxel-resistant glioma cells (SHG-44 RE) compared to their sensitive counterparts (SHG-44).
- Down-regulation of lncRNA PVT1 in SHG-44 RE cells led to decreased cell viability and increased apoptosis following paclitaxel treatment.
- These findings indicate that inhibiting lncRNA PVT1 enhances the sensitivity of human glioma cells to paclitaxel.
Conclusions:
- Down-regulation of lncRNA PVT1 can enhance chemosensitivity to paclitaxel, induce apoptosis, and inhibit proliferation in glioma cells.
- Targeting lncRNA PVT1 presents a potential strategy to overcome paclitaxel resistance in clinical cancer medicine.
- Further research into lncRNA PVT1's role could lead to improved therapeutic approaches for glioma patients experiencing drug resistance.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Resistivity
Resistance
RNA Structure
The basic structure of RNA consists of a five-carbon sugar and one of four nitrogenous bases. Although most RNA is single-stranded, it can form complex secondary and tertiary structures. Such structures play essential roles in the regulation of transcription and translation.
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA): messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three RNA types consist of a...


